Generic Medicine Info
May be taken with or without food.
Special Precautions
Patient w/ predisposition to nephrolithiasis, conditions or medications that may increase risk of metabolic acidosis, history of eye disorders. Renal and hepatic impairment. Childn. Pregnancy and lactation. Patient Counselling This drug may cause visual disturbances, drowsiness, and dizziness, if affected do not drive or operate machinery. Maintain proper hydration while on therapy, esp during exercise or exposure to warm weather. Avoid abrupt withdrawal. Monitoring Parameters Monitor electrolytes (e.g. serum bicarbonate) at baseline and periodically during treatment), serum creatinine, symptoms of acute acidosis and complications of long-term acidosis, hydration status, seizure frequency, and suicidality.
Adverse Reactions
Confusion, ataxia, impaired concentration and speech, fatigue, depression, dizziness, paraesthesia or hypoaesthesia, drowsiness, memory or cognition difficulty, anxiety, agitation, nervousness, emotional lability, mood disorders, anorexia, abdominal pain, asthenia, diplopia, leucopenia, nausea, diarrhoea, nystagmus, insomnia, psychomotor retardation, nasopharyngitis, altered taste, visual disturbances, wt loss, increased risk of renal calculi, reduced sweating w/ hyperthermia. Rarely, acute myopia w/ secondary angle-closure glaucoma.
Drug Interactions
Decreased serum level w/ other antiepileptics (e.g. carbamazepine, phenytoin). May increase effect of CNS depressants. May reduce efficacy and increase risk of breakthrough bleeding of OCs. May increase AR (e.g. metabolic acidosis) of metformin and other carbonic anhydrase inhibitors (e.g. acetazolamide). May increase serum level of lithium.
CIMS Class
ATC Classification
N03AX11 - topiramate ; Belongs to the class of other antiepileptics.
Disclaimer: This information is independently developed by CIMS based on topiramate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in